InfuSystem sees ‘acceleration’
By HME News Staff
Updated 7:54 AM CST, Thu November 7, 2024
ROCHESTER HILLS, Mich. – InfuSystem Holdings reported revenue of $35.3 million for the third quarter of 2024, an increase of 11% year over year. Of that, Patient Services net revenue was $20.8 million and Device Solutions net revenue was $14.5 million. Adjusted EBITDA was $7.9 million, an increase of 15% year over year. “Our third quarter financial results reflect the forecasted acceleration in our business in the second half of the year,” said Rich Dilorio, CEO. “We saw significant growth in both our top- and bottom-line results, accompanied by strong cash flow. The record revenue of $35.3 million, which represents organic growth of 11% was driven by strong growth in our oncology and rental businesses, and ramping revenue in wound care third-party payer revenues.” During the quarter, InfuSystem entered into strategic partnerships with Smith+Nephew to distribute its negative pressure wound therapy system and Sanara Medtech to become the exclusive distributor of the Chemo Mouthpiece.
Comments